P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS

Ítems similars

• Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
  per: Allison Rosenthal, et al.
  Publicat: (2024-08-01)
• P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
  per: Andrew Ip, et al.
  Publicat: (2023-08-01)
• Metabolic pitfall of pseudoprogression after epcoritamab treatment
  per: Osamu Imataki, et al.
  Publicat: (2024-12-01)
• Implementation of IEEE 1149.1 on system-on-chip /
  per: Neoh, Justin Soon Teong, 1985-, et al.
  Publicat: (2009)
• Sp1149. II. Spectroscopy of H ii Regions near the Critical Curve of MACS J1149 and Cluster Lens Models
  per: Hayley Williams, et al.
  Publicat: (2024-01-01)